Navigation Sciences

Real-Time Margin Measurement for Precision Cancer Surgery

Receive Newsletter

Home

Real-Time Margin Measurement for Precision Cancer Surgery

Real-Time Margin Measurement

for Precision Cancer Surgery

Addressing Unmet Needs in Soft Tissue Surgery

Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.

Real-time GPS Navigation

Real-time GPS
Navigation

Minimally Invasive

Precise Margin
Control

icon-minimally-invasive

Minimally
Invasive

The NaviSci System, which recently completed a clinical feasibility trial, has great potential to:

  • Reduce early-stage cancer recurrence risk
  • Conserve lung function
  • Improve surgical workflow
  • Shorten hospital length of stay

NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.

Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.

Addressable U.S. market opportunity Infographic

Recent News

Download Navigation Sciences Executive Summary

NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team

Info@navigationsci.com
Brookline, MA